What the research examined
Two phase 2 trials examined retatrutide in distinct populations: adults with obesity and people with type 2 diabetes. Investigators measured weight-related or glycemic endpoints and reported gastrointestinal adverse events. The obesity trial also described heart-rate changes.
How to interpret the findings
Different populations, comparators, and endpoints prevent simple cross-trial rankings. These papers do not constitute a head-to-head comparison with every alternative or establish a current regulatory status. Trial observations apply to the investigated formulation.
Research literature
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
The New England journal of medicine · 2023 · PMID 37366315 - Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
Lancet (London, England) · 2023 · PMID 37385280
Links open the indexed paper records. Summaries are based on those records and their available abstracts, not a systematic review or a full-text appraisal of every study.